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Quebec City, Quebec, Vancouver, British Columbia, and Toronto, Ontario, Canada;
and Barcelona, SpainObjectives The aim of this study was to determine the impact of new-onset persistent left bundle
branch block (NOP-LBBB) on late outcomes after transcatheter aortic valve implantation (TAVI).
Background The impact of NOP-LBBB after TAVI remains controversial.
Methods A total of 668 consecutive patients who underwent TAVI with a balloon-expandable valve
without pre-existing LBBB or permanent pacemaker implantation (PPI) were included. Electrocardiograms
were obtained at baseline, immediately after the procedure, and daily until hospital discharge. Patients
were followed at 1, 6, and 12 months and yearly thereafter.
Results New-onset LBBB occurred in 128 patients (19.2%) immediately after TAVI and persisted at
hospital discharge in79patients (11.8%). At amedian follow-upof 13months (range3 to 27months), there
were no differences in mortality rate between the NOP-LBBB and no NOP-LBBB groups (27.8% vs. 28.4%;
adjusted-hazard ratio: 0.87 [95% conﬁdence interval (CI): 0.55 to 1.37]; p¼ 0.54). Therewere no differences
between groups regarding cardiovascularmortality (p¼ 0.82), sudden death (p¼ 0.87), rehospitalizations
for all causes (p ¼ 0.11), or heart failure (p ¼ 0.55). NOP-LBBB was the only factor associated with an
increased rate of PPI during the follow-up period (13.9% vs. 3.0%; hazard ratio: 4.29 [95% CI: 2.03 to 9.07],
p < 0.001. NOP-LBBB was also associated with a lack of left ventricular ejection fraction improvement
and poorer New York Heart Association functional class at follow-up (p < 0.02 for both).
Conclusions NOP-LBBB occurred in w1 of 10 patients who had undergone TAVI with a balloon-
expandable valve. NOP-LBBB was associated with a higher rate of PPI, a lack of improvement in left
ventricular ejection fraction, and a poorer functional status, but did not increase the risk of global
or cardiovascular mortality or rehospitalizations at 1-year follow-up. (J Am Coll Cardiol Intv
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129The dismal prognosis associated with symptomatic severe Lung Institute [Quebec City, Quebec, Canada]: n ¼ 220;
aortic stenosis when left untreated is dramatically improved
by standard aortic valve replacement (SAVR). However,
despite its ability to relieve valvular obstruction, some studies
have shown that patients undergoing SAVR have a poorer
survival than that expected for the general population due
partially to an excess of cardiovascular mortality and, spe-
ciﬁcally, sudden death (1). Among the factors associated
with increased late mortality after SAVR, the occurrence of
new-onset left bundle branch block (LBBB) has been
associated with a higher risk of sudden death (2,3).See page 137
Abbreviations
and Acronyms
AVB = atrioventricular block
CI = conﬁdence interval
ECG = electrocardiographic
IQR = interquartile range
LBBB = left bundle branch
block
LVEF = left ventricular
ejection fraction
NOP-LBBB = new-onset
persistent left bundle branch
block
NYHA = New York Heart
Association
PPI = permanent pacemaker
implantation
SAVR = surgical aortic valve
replacement
TAVI = transcatheter aortic
valve implantation
VARC = Valve Academic
Research ConsensusTranscatheter aortic valve implantation (TAVI) has been
established as a therapeutic option for patients with aortic
stenosis considered to be at high or prohibitive surgical risk
(4). The occurrence of new-onset LBBB is one of the most
frequent complications after TAVI (5). Although the inci-
dence and predictive factors of new conduction disturbances
after TAVI have been well studied, data on the potential
prognostic value of this conduction abnormality are scarce
and controversial. Recently, 2 studies using mainly or
exclusively the self-expandable CoreValve system (Med-
tronic, Minneapolis, Minnesota) reported opposite results;
whereas Houthuizen et al. (6) showed a higher mortality rate
at 1-year follow-up in patients who had a new-onset LBBB
after TAVI, Testa et al. (7) failed to show any impact of
new-onset LBBB after TAVI on mortality or on the rate of
rehospitalizations for heart failure, unlike other previous
studies showing that the appearance of new LBBB may
trigger heart failure even in patients without overt cardiac
disease (8,9). It is known that major differences exist be-
tween the self- and balloon-expandable valves regarding the
incidence and evolution of conduction disturbances over
time (5,10,11), and little evidence exists regarding balloon-
expandable valves (11). The aim of this study was, therefore,
to determine the impact of new-onset persistent (NOP)
LBBB on late clinical outcomes in a large cohort of patients
who had undergone TAVI with a balloon-expandable valve.
Methods
Study population. A total of 985 consecutive patients with
symptomatic aortic stenosis considered not suitable for or
at very high risk of SAVR underwent TAVI with a bal-
loon-expandable valve at 4 centers. Of them, a total of 317
patients were excluded for the following reasons: aborted
procedure without valve implantation (n ¼ 20), procedural
death (n ¼ 7), previous permanent pacemaker implantation
(PPI) (n ¼ 152), pre-existing LBBB (n ¼ 83), and PPI
during hospitalization (n ¼ 55). The ﬁnal study population
consisted of 668 patients (St. Paul’s Hospital [Vancouver,
British Columbia, Canada]: n ¼ 303; Quebec Heart andSt. Michael’s Hospital [Toronto, Ontario, Canada]: n ¼ 86;
Hospital Universitari Vall d’Hebron [Barcelona, Spain]:
n ¼ 59). Of these, 168 patients from both the Quebec Heart
and Lung Institute and Hospital Universitari Vall d’Hebron
had already been included in a previous study (11). Details
on the TAVI procedure are provided elsewhere (4). Data
were prospectively collected in a dedicated database at each
center. The study protocol was in accordance with the
institutional ethics committee of each participating center,
and all patients gave informed written consent for the pro-
cedures. The need for consent to participate in this research
study was waived in view of its observational and anony-
mous nature. Periprocedural events were deﬁned according
to the Valve Academic Research Consensus (VARC) 2
criteria (12).
Electrocardiographic data. Elec-
trocardiographic (ECG) records
were obtained from all patients at
baseline, immediately after the
procedure, and daily until hospital
discharge. ECG tracings were
analyzed by a cardiologist at each
center. The diagnosis of intra-
ventricular conduction abnor-
malities was based on American
Heart Association/American Col-
lege of Cardiology Foundation/
Heart Rhythm Society recom-
mendations for the standardiza-
tion and interpretation of the
electrocardiogram (13). PPI was
indicated if third-degree or ad-
vanced second-degree atrioven-
tricular block (AVB) was found
at any anatomic level that was not
expected to resolve after the
intervention and for sinus node
dysfunction with documented
symptomatic bradycardia, in agreement with the American
Heart Association/American College of Cardiology Foun-
dation/Heart Rhythm Society guidelines for device-based
therapy of cardiac rhythm abnormalities (14).
NOP-LBBB was deﬁned as any new LBBB occurring
during the hospitalization period after the TAVI procedure
that persisted at hospital discharge, including patients who
died during the hospitalization period without proven res-
olution of the LBBB.
Follow-up. Follow-up was carried out by clinical outpatient
visits or telephone interviews at 30 days, 6 months, and 1
year, and yearly thereafter. The median follow-up was 13
months (interquartile range [IQR]: 3 to 27 months), and no
patient was lost to follow-up. All clinical events were deﬁned
according to the VARC 2 criteria, and any death was
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130recorded and further classiﬁed as of cardiovascular or
noncardiovascular cause (12). Any death of unknown cause
was considered cardiovascular mortality as recommended by
the VARC 2 criteria. Sudden cardiac death was deﬁned as
any unexpected death due to cardiac disease that occurred
within 1 h after of the onset of symptoms (15). Rehospi-
talizations for all causes and heart failure were recorded
during the follow-up period. Physicians responsible for the
patients were contacted and/or medical charts were reviewed
to determine the causes of rehospitalization and/or death
when necessary.
Transthoracic echocardiography examinations were per-
formed at baseline, at hospital discharge, and at 6- and
12-month follow-up. Echocardiographic data at follow-up
were available for 341 patients (83% of the patients who
reached the 6- and 12-month follow-up).
Statistical analysis. Qualitative variables are expressed as
percentages and compared using the chi-square or Fisher
exact test as appropriate. Continuous variables are given as
mean  SD or median (IQR) and compared using a 2-sided
t test or Wilcoxon rank sum test depending on the variable
distribution. Comparisons of clinical outcomes between
NOP-LBBB and no NOP-LBBB patients were adjusted for
baseline differences between groups using a logistic regression
analysis (30-day mortality) or proportional hazards model
(latemortality) that included variables with a p value<0.10 on
univariate analysis. The following variables were included in
the model: age, hypertension, diabetes mellitus, approach,
and prosthesis size. A landmark analysis with a landmark
cutoff at 30 days was used to further investigate the impact of
NOP-LBBB on late mortality. To analyze factors associated
with late PPI, a Fine-Gray Cox model was constructed to
account for death as a competing risk event for the need of
PPI. Survival curves were constructed using Kaplan-Meier
estimates, and the log-rank test was used for between-group
comparisons. Changes in left ventricular ejection fraction
(LVEF) over time between groups were compared using a
repeated-measures model with interactions. Further com-
parisons were performed using the Tukey technique. The
predictors of signiﬁcant LVEF changes over time were
determined using a multivariate regression linear model
including variables with a p value<0.10 on univariate analysis.
Variables included in the model were hypertension, LVEF at
baseline, transapical/transaortic approach, and NOP-LBBB.
A p value <0.05 was considered statistically signiﬁcant. An-
alyses were conducted using the statistical package SAS,
version 9.2 (SAS Institute Inc., Cary, North Carolina).
Results
New-onset LBBB occurred in 128 patients (19.2%) imme-
diately after the procedure. Of these, LBBB persisted at
hospital discharge in 79 patients (11.8%; 56.4% of patients
with new-onset LBBB). Baseline clinical characteristics,ECG and echocardiographic ﬁndings, procedural variables,
and in-hospital outcomes according to the occurrence of
NOP-LBBB are shown in Table 1. Patients who had NOP-
LBBB were younger (p ¼ 0.006), had a higher prevalence of
hypertension (p ¼ 0.040) and diabetes mellitus (p ¼ 0.005),
and more frequently underwent the TAVI procedure
through transapical approach (p ¼ 0.005) and received a 29-
mm valve (p ¼ 0.041). Transapical approach (odds ratio:
1.90 [95% conﬁdence interval (CI): 1.15 to 3.16]; p¼ 0.013)
and a larger valve size (29-mm valve) (odds ratio: 3.12 [95%
CI: 1.22 to 7.97]; p ¼ 0.017) remained as independent
predictors of NOP-LBBB in the multivariate analysis.
NOP-LBBB and mortality. At a median follow-up of 13
months (IQR: 3 to 27 months), a total of 189 patients
(28.3%) had died; causes of death were classiﬁed as non-
cardiovascular in 75 patients (39.7%) and cardiovascular in
114 patients (60.3%). Sudden death occurred in 7 patients
(1.0%, all during the follow-up period).
A total of 22 patients (27.8%) with NOP-LBBB died
during the study period, 16 from cardiovascular causes
(20.3%, sudden death: 1.3%). There were no differences be-
tween the NOP-LBBB and no NOP-LBBB groups
regarding overall mortality (NOP-LBBB: 27.8%, no NOP-
LBBB: 28.4%; hazard ratio [HR]: 0.83 [95% CI: 0.53 to
1.29]; p¼ 0.401 [p¼ 0.431 after adjusting for age differences,
p ¼ 0.538 after adjusting for baseline differences]), cardio-
vascular mortality (NOP-LBBB: 20.3%, no NOP-LBBB:
16.6%; HR: 1.03 [95% CI: 0.61 to 1.76]; p ¼ 0.906 [p ¼
0.888 after adjusting for age differences, p ¼ 0.820 after
adjusting for baseline differences]), or sudden death (NOP-
LBBB: 1.3%, noNOP-LBBB: 1.0%;HR: 0.91 [95%CI: 0.11
to 7.65]; p ¼ 0.932 [p ¼ 0.974 after adjusting for age differ-
ences, p ¼ 0.872 after adjusting for baseline differences])
(Table 2). This lack of association between NOP-LBBB and
mortality persisted when a landmark analysis with a cutoff at
30 days (before and after 30 days) was performed (Table 2).
Survival curves for all-cause mortality, cardiovascular mor-
tality, and sudden death are shown in Figure 1.
NOP-LBBB and PPI. Of the 668 patients discharged alive
without PPI after TAVI, 29 patients (4.3%), 11 (13.4%)
patients with NOP-LBBB and 18 (3.0%) of patients without
NOP-LBBB required PPI after a median follow-up of 13
months (IQR: 3 to 27months). The median time for PPI was
12 months (IQR: 5 to 38 months). PPI was needed due to a
high degree of or complete AVB, sinus node dysfunction,
symptomatic bradycardia, and slow atrial ﬁbrillation in 16
(55.5%), 6 (20.7%), 4 (13.8%), and 3 (10.3%) patients,
respectively. A high degree of or complete AVB was the
reason for PPI at follow-up in 8 of the 9 patients with NOP-
LBBB. Individual characteristics of patients requiring PPI
during the follow-up period are shown in Online Table 1.
NOP-LBBB was the only independent predictor of PPI
during the follow-up period, even when considering death as a
competing risk event (HR: 4.29 [95% CI: 2.03 to 9.07];
Table 1. Baseline and Procedural Variables According to the
Occurrence of NOP-LBBB (n ¼ 668)
No NOP-LBBB
(n ¼ 589)
NOP-LBBB
(n ¼ 79)
p
Value
Clinical characteristics
Age, yrs 81  8 78  9 0.006
Male 286 (48.6) 39 (49.4) 0.905
Body mass index, kg/m2 26  6 27  6 0.200
Hypertension 473 (80.3) 71 (89.9) 0.040
Diabetes mellitus 169 (28.7) 35 (44.3) 0.005
COPD 161 (27.3) 22 (27.8) 0.923
NYHA functional class >II 452 (76.7) 62 (78.5) 0.730
eGFR <60 ml/min 260 (44.1) 33 (41.8) 0.719
Coronary artery disease 401 (68.1) 58 (73.4) 0.261
Previous CABG 189 (32.1) 32 (40.5) 0.135
STS-PROM score, % 7.9  4.9 7.6  4.6 0.568
Log EuroSCORE, % 21.2  14.1 20.8  13.9 0.844
Echocardiography
LVEF, % 56  13 56  11 0.841
Mean gradient, mm Hg 47  17 45  17 0.380
Aortic valve area, cm2 0.60 (0.50–0.77) 0.62 (0.55–0.78) 0.504
PSAP >60 mm Hg 75 (12.7) 12 (15.2) 0.508
Procedural variables
Procedural success 531 (90.2) 70 (88.6) 0.668
Valve in valve 25 (4.2) 3 (3.8) 0.999
Approach
Transfemoral 333 (56.5) 30 (38.0) 0.001
Transapical 237 (40.2) 49 (62.0)
Transaortic 19 (3.2) 0
Prosthesis type
Cribier-Edwards 37 (6.3) 2 (2.5) 0.440
Edwards Sapien 299 (50.8) 46 (58.2)
Sapien XT 247 (41.9) 31 (39.2)
Sapien 3 6 (1.0) 0
Prosthesis size, mm
20–23 274 (46.5) 35 (44.3) 0.041
26 294 (49.9) 36 (45.6)
29 21 (3.6) 8 (10.1)
In-hospital outcomes
Moderate or more
residual AR
74 (12.5) 9 (11.4) 0.763
Myocardial infarction 9 (1.5) 1 (1.3) 0.999
Major vascular
complications
50 (8.4) 7 (8.9) 0.922
Major or life-threatening
bleeding
124 (21.1) 13 (16.5) 0.342
Dialysis 5 (0.8) 1 (1.3) 0.532
Stroke 14 (2.4) 4 (5.1) 0.254
Death 29 (4.9) 5 (6.3) 0.594
Values are mean  SD, n (%), or median (interquartile range).
AR ¼ aortic regurgitation; CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive
pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate; Log EuroSCORE: Logistic Euro-
SCORE (European System for Cardiac Operative Risk Evaluation)-predicted risk of mortality; LVEF ¼
left ventricular ejection fraction; NOP-LBBB ¼ new-onset persistent left bundle branch block;
NYHA ¼ New York Heart Association; PASP ¼ pulmonary artery systolic pressure; STS-PROM ¼
Society of Thoracic Surgeons predicted risk of mortality.
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131p < 0.001). Survival curves showing freedom from PPI over
time are shown in Figure 2.
NOP-LBBB, rehospitalizations, and functional status. A total
of 281 patients (42.1%) needed rehospitalization at a
median follow-up of 13 months (IQR: 3 to 27 months),
85 of them (12.7%, 30.2% of total hospitalizations) due to
heart failure. There was no association between NOP-
LBBB and hospitalizations for all causes (55.7% vs. 40.2%;
HR: 1.27 [95% CI: 0.91 to 1.77]; p ¼ 0.154 [p ¼ 0.138
after adjusting for age differences, p ¼ 0.112 after
adjusting for baseline differences]) or heart failure (16.5%
vs. 12.2%; HR: 1.30 [95% CI: 0.72 to 2.35]; p ¼ 0.390
[p ¼ 0.409 after adjusting for age differences, p ¼ 0.546
after adjusting for baseline differences]) (Table 3).
Differences in New York Heart Association (NYHA)
functional class at baseline and follow-up period across the
study groups are shown in Figure 3. NOP-LBBB was
associated with a poorer NYHA functional class at the
6- and 12-month follow-up (p ¼ 0.015).
NOP-LBBB, valve hemodynamics, and LVEF. Changes in
LVEF between baseline and follow-up are shown in Figure 4.
The presence of hypertension (estimated coefﬁcient: 3.37
[95% CI: 6.66 to 0.76]; p ¼ 0.045), a higher LVEF at
baseline (estimated coefﬁcient: 7.69 [95% CI: 8.72
to 6.66]; p < 0.001), the use of transapical approach
(estimated coefﬁcient: 2.89 [95% CI: 5.45 to 0.31];
p ¼ 0.028), and the occurrence of NOP-LBBB (estimated
coefﬁcient: 4.70 [95% CI: 8.41 to 0.99]; p ¼ 0.006)
were associated with a lower improvement in LVEF over
time. In the multivariate analysis, a higher LVEF at baseline
and the occurrence of NOP-LBBB were the only indepen-
dent predictors of the lack of improvement in LVEF at
follow-up (estimated coefﬁcients: 7.58 [95% CI: 8.60
to 6.55] and 4.00 [95% CI: 6.91 to –1.10]; p ¼ 0.007,
R2 ¼ 0.422, respectively).
Discussion
The rate of new-onset LBBB of w20% observed in the
present study is similar to that reported in previous studies of
TAVI using balloon-expandable valves (5,11,16). Also in
accordance with previous studies, about one-half of the
conduction disturbances occurring after balloon-expandable
valve implantation resolved within the few days after the
procedure, leading to a rate of NOP-LBBB of w10% (11).
Previous studies have shown that, unlike transient conduc-
tion disturbances, NOP-LBBB is partially determined by
factors such as a lower (more ventricular) implantation of the
stent valve frame, which is probably associated with more
permanent mechanical damage of the left conduction system
(11,17,18). Also, the use of both the transapical approach
and 29-mm valves was associated with a higher incidence of
NOP-LBBB, may be due to a greater damage of the ven-
tricular septum in these cases. However, these observations
Table 2. NOP-LBBB and Mortality After Transcatheter Aortic Valve
Implantation
Cause of Death
No NOP-LBBB
(n ¼ 589)
NOP-LBBB
(n ¼ 79) p Value
All cause
Univariate HR/OR
Cumulative 1.00 0.83 (0.53–1.29) 0.401
30 days 1.00 1.26 (0.51–3.01) 0.611
>30 days to maximum 1.00 0.73 (0.44–1.23) 0.240
Age-adjusted HR/OR
Cumulative 1.00 0.84 (0.53–1.31) 0.431
30 days 1.00 1.32 (0.53–3.25) 0.552
>30 days to maximum 1.00 0.73 (0.43–1.24) 0.244
Multivariate-adjusted HR/OR
Cumulative 1.00 0.87 (0.55–1.37) 0.538
30 days 1.00 1.47 (0.57–3.75) 0.423
>30 days to maximum 1.00 0.75 (0.44–1.29) 0.300
Cardiovascular
Univariate HR/OR
Cumulative 1.00 1.03 (0.61–1.76) 0.906
30 days 1.00 1.26 (0.47–3.35) 0.644
>30 days to maximum 1.00 0.88 (0.45–1.71) 0.702
Age-adjusted HR/OR
Cumulative 1.00 1.04 (0.61–1.78) 0.888
30 days 1.00 1.26 (0.47–3.37) 0.643
>30 days to maximum 1.00 0.88 (0.45–1.73) 0.718
Multivariate-adjusted HR/OR
Cumulative 1.00 1.07 (0.62–1.85) 0.820
30 days 1.00 1.46 (0.53–4.04) 0.468
>30 days to maximum 1.00 0.90 (0.44–1.75) 0.704
Sudden death
Univariate HR/OR
Cumulative 1.00 0.91 (0.11–7.65) 0.932
30 days d d d
>30 days to maximum d d d
Age-adjusted HR/OR
Cumulative 1.00 0.97 (0.11–8.20) 0.974
30 days d d d
>30 days to maximum d d d
Multivariate-adjusted HR/OR
Cumulative 1.00 0.84 (0.10–7.39) 0.872
30 days d d d
>30 days to maximum d d d
Values are hazard ratio (HR)/odds ratio (OR) (95% conﬁdence interval).
NOP-LBBB ¼ new-onset persistent left bundle branch block.
Figure 1. Survival Curves at 1-Year Follow-Up
Kaplan-Meier survival curves at 1-year follow-up for overall mortality
(A), cardiac mortality (B), and sudden cardiac death (C), according to
the occurrence of new-onset persistent left bundle branch block
(NOP-LBBB).
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132must be interpreted with caution because this study was not
designed to evaluate the predictors of NOP-LBBB.
NOP-LBBB and mortality. The presence of LBBB has been
classically considered a marker of poorer long-term survival in
patients with pre-existing cardiac disease (8,9) and in appar-
ently healthy individuals without overt disease (8,19). It has
been shown that LBBB can affect the hemodynamic and
electrical performance of the heart, leading to mechanical
Figure 2. Permanent Pacemaker Implantation at 1-Year Follow-Up
Kaplan-Meier curves at 1-year follow-up showing freedom from permanent
pacemaker implantation (A) and freedom from pacemaker implantation due
to advanced or complete atrioventricular block (B), according to the occur-
rence of new-onset persistent left bundle branch block (NOP-LBBB).
Table 3. NOP-LBBB and the Risk of Rehospitalization
No NOP-LBBB
(n ¼ 589)
NOP-LBBB
(n ¼ 79) p Value
Rehospitalizations for all causes
Univariate HR/OR 1.00 1.27 (0.91–1.77) 0.154
Age-adjusted HR/OR 1.00 1.29 (0.92–1.79) 0.138
Multivariate-adjusted HR/OR 1.00 1.32 (0.94–1.86) 0.112
Rehospitalizations for heart failure
Univariate HR/OR 1.00 1.30 (0.72–2.35) 0.390
Age-adjusted HR/OR 1.00 1.29 (0.71–2.34) 0.409
Multivariate-adjusted HR/OR 1.00 1.21 (0.66–2.22) 0.546
Values are HR/OR (95% conﬁdence interval).
Abbreviations as Table 2.
Figure 3. Functional Status and NOP-LBBB
Changes in New York Heart Association (NYHA) functional class over time
according to the occurrence of new-onset persistent left bundle branch block
(NOP-LBBB).
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133ventricular asynchrony, which in turn can result in increased
end-systolic volumes, septal hypertrophy, abnormal perfu-
sion, and an impairment of systolic and diastolic ventricular
performance (20). It is not known, however, whether the
presence of LBBB is directly associated with higher mortality
or is merely an indicator of the severity of underlying cardiac
disorders. Importantly, in most of the studies showing a
relationship between LBBB and mortality, the follow-up was
very long, ranging from 3 to 30 years (2,3,19,21).
The occurrence of new-onset LBBB after SAVR has been
a matter of concern, and studies on the impact of new LBBB
on late mortality after SAVR have provided different results
(2,3,21–24). The relatively limited sample size of all of
these studies, differences between studies regarding inclusioncriteria (any new LBBB vs. only NOP-LBBB), and consid-
erable variability in the length of follow-up may partially
explain these differences.
Very few data exist on the clinical impact of new-onset
LBBB after TAVI. Three previous studies have shown a
negative effect of new-onset LBBB on left ventricular
function at 1-year follow-up, with either a lack of improve-
ment or even reduction in LVEF in those patients with new
LBBB (11,25,26), in accordance with the results of this
study. However, the clinical relevance of these changes in
ventricular function remains to be determined. More
recently, Houthuizen et al. (6) reported a higher rate of all-
cause mortality and cardiovascular mortality at 1-year follow-
up in those patients in whom new LBBB after TAVI
developed. These results differ from those reported in the
present study, in which NOP-LBBB was not associated with
any increase in overall or cardiovascular mortality. Although
the sample size and length of follow-up were similar in the
Figure 4. Left Ventricular Ejection Fraction and NOP-LBBB
Changes in left ventricular ejection fraction after transcatheter aortic valve
implantation, according to the occurrence of new-onset persistent left bundle
branch block (NOP-LBBB).
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1342 studies, some signiﬁcant differences should be highlighted.
First, the global risk of the patients included in this study was
higher (logistic EuroSCORE [European System for Cardiac
Operative Risk Evaluation] of w21% vs. 16%), most likely
related to a higher prevalence of cardiac and noncardiac
comorbidities, and this also translated into a higher cumu-
lative mortality rate (28.3% vs. 20.6%). The potential clinical
impact of new conduction abnormalities after TAVI may
differ between moderate- and high-risk patients, partially
due to differences in the relative weight of comorbidities in
clinical outcomes. Second, the present study included only
patients with new LBBB that persisted at hospital discharge,
whereas the Houthuizen et al. (6) study included patients
with any new LBBB within 7 days after TAVI. This may be
particularly relevant when using the balloon-expandable
Edwards system (Edwards Lifesciences Corporation, Irvine,
California), for which the occurrence of new LBBB is
transient (recovery within a few hours or days) in about one-
half of the cases (11). Finally, another important difference
between the 2 studies is the use of different transcatheter
valve systems. Although the present study evaluated only
patients who underwent TAVI with a balloon-expandable
transcatheter heart valve system, Houthuizen et al. (6)
included a mix of self- and balloon-expandable valves, with
the majority of patients receiving a self-expandable Cor-
eValve system (Medtronic), and the incidence and evolution
over time of conduction disturbances are different between
the 2 balloon- and self-expandable valve systems (10,11). In
accordance with the results of our study, Testa et al. (7) did
not ﬁnd any association between new LBBB and all-causeand cardiovascular mortality at 1-year follow-up in a large
cohort of patients who underwent self-expandable trans-
catheter valve implantation. Two of the main differences
with respect to the Houthuizen et al. (6) study were the in-
clusion of higher-risk patients (mean logistic EuroSCORE
of w23%) and the inclusion of persistent LBBB (vs. new-
onset LBBB). These differences between studies may
partially explain the controversial results regarding the clin-
ical impact of new LBBB after TAVI, but this will need to be
further evaluated in future studies.
NOP-LBBB and PPI at 1-year follow-up. A high risk of AVB
has been observed in patients and individuals without overt
cardiac disease in the presence of LBBB (27,28). Previous
studies including a relatively small number of patients showed
a higher rate of PPI at follow-up among those patients in
whom a new LBBB developed after either SAVR or TAVI
(2,11,29). The present study conﬁrmed these results in a large
cohort of patients who had received a balloon-expandable
valve. Of note, patients with NOP-LBBB that progressed
toward an advanced or complete AVB accounted for almost
one-half (46%) of PPIs required during the ﬁrst year after
TAVI, and 53% of PPIs were due to complete AVB during
the study period.After the immediatemechanical injury of the
left bundle branch after valve implantation, a further late
injury of the conduction system related to an inﬂammatory or
cicatrization process may explain these late conduction dis-
turbances Also, the occurrence of NOP-LBBBmay identify a
group of patients more prone to the development of con-
duction abnormalities, which would require PPI at midterm
follow-up. Testa et al. (7) found a higher rate of PPI in the
NOP-LBBB group at 1 month after TAVI, but this differ-
ence was no longer signiﬁcant at 1-year follow-up. Interest-
ingly, the rate of PPI among patients with new LBBB was
18%, slightly higher than the 13% observed in our study.
However, the rate of PPI at 1-year follow-up among pa-
tients with no conduction disturbances at hospital discharge
was as high as 17%, and this was much higher than the 3%
observed in our study. Therefore, the differences between
the 2 studies may be explained by the very high rate of PPI
during the follow-up period in patients without conduction
disturbances after self-expandable valve implantation, much
higher than that expected according to the age of the study
population. Future studies including a much larger number
of patients will be needed to elucidate the factors associated
with the progression of conduction disturbances and the
need for PPI late after TAVI with balloon- and self-
expandable transcatheter valves.
NOP-LBBB, LVEF, functional status, and rehospitalizations.
Previous studies have shown the deleterious effect of
NOP-LBBB on LVEF after TAVI, with either a lack of
improvement or even a decrease in LVEF compared with
patients with no new conduction abnormalities (11,25,26).
In accordance with these studies, a lack of improvement in
LVEF at 6 to 12 months after TAVI was also observed in
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compared with an increase in LVEF in patients with no
NOP-LBBB. Also, patients with NOP-LBBB exhibited an
impaired functional status at follow-up, with 18% of the
patients in NYHA functional class higher than II compared
with only 7% of the patients with no new conduction ab-
normalities after TAVI. These results differ from those re-
ported by Testa et al. (7), showing the lack of differences in
LVEF changes and NYHA functional class at follow-up
between patients with and without new LBBB after TAVI
with a self-expandable valve. As mentioned previously, in
the work of Testa et al. (7), there was a rate of PPI as high as
17% within the year after TAVI in patients with no new
LBBB (similar to the 18% in patients with new LBBB), and
this may have been associated with LV mechanical dyssyn-
chrony similar to that of LBBB. In addition, a tendency
toward a higher rate of moderate or severe paravalvular leaks
was also observed in the new LBBB group, and this might
also have mitigated the potential differences in LVEF and
NYHA functional class between the NOP-LBBB and no
NOP-LBBB groups.
The appearance of a new LBBB has been associated with a
higher incidence of rehospitalizations secondary to decom-
pensated heart failure in patients with a diagnosis of heart
failure (8) and in those without overt cardiac disease (9).
NOP-LBBB was not associated with a higher rate of reho-
spitalizations due to heart failure in the present study, and this
was in accordance with previous studies in the TAVI ﬁeld
(7,11). Most patients had normal LVEF pre-TAVI, and
longer-term follow-up may be necessary to detect an increase
in rehospitalizations secondary to LV mechanical dyssyn-
chrony in these patients. Also, the number of events was
limited, and a larger sample size with a longer follow-up may
be needed to detect differences between groups.
Study limitations. The study was not designed to conﬁrm
the null hypothesis. Although the electrocardiograms were
evaluated by experienced cardiologists in each center, there
was no centralized core laboratory for ECG analysis. There
was no central committee to adjudicate clinical events, and
although centers followed the VARC 2 deﬁnitions, this
might be relevant for the classiﬁcation of mortality events as
cardiovascular versus noncardiovascular. However, this
probably has only minor importance with respect to overall
mortality or PPI (yes/no) events. Finally, the duration of the
follow-up was relatively short, and this might have led to an
underestimation of the impact of LBBB, especially in view
of the fact that studies evaluating the relationship between
LBBB and mortality in non-TAVI candidates had a follow-
up ranging from 3 to 30 years (2,3,8,24).
Conclusions
The occurrence of conduction disturbances, and particularly
of LBBB, remains an important issue in the TAVI ﬁeld.Determining the prognostic value of these conduction dis-
turbances is of major clinical relevance, especially consid-
ering that speciﬁc therapies (e.g., PPI, resynchronization)
might be applied to potentially modify clinical outcomes.
The present study showed that NOP-LBBB after TAVI
with a balloon-expandable valve was not associated with any
increased risk of mortality (overall and cardiovascular) or
rehospitalization (any cause or heart failure) at 1-year follow-
up. However, NOP-LBBB was associated with a higher rate
of advanced or complete AVB requiring PPI and predicted a
lack of LVEF improvement and poorer functional status
after TAVI. Future studies will have to further evaluate both
the clinical impact of left ventricular changes and the factors
associated with the further progression of conduction dis-
turbances in patients in whom LBBB develops after TAVI.
Continuous follow-up of these patients over time is
mandatory to determine the impact of NOP-LBBB at
longer term follow-up.
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